Health Care·Pharmaceuticals·$3.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | -8.25% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.42 | N/A | -8.25% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern about current market conditions. They are focused on navigating challenges and maintaining stability.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Edgewise Therapeutics reported a loss that was slightly worse than expected, leading to a 2.45% decline in stock price. Investors may be concerned about the lack of revenue details and guidance, which contributes to uncertainty about the company's future performance. The management's defensive tone suggests they are aware of the challenges ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
APELLIS PHARMACEUTIC
Feb 28, 2025